How should mild hyperkalaemia be managed?

Management of Mild Hyperkalemia (Potassium 5.11 mEq/L)

For a potassium of 5.11 mEq/L, you should NOT routinely discontinue RAAS inhibitors if the patient is taking them; instead, identify and address reversible causes, optimize diuretic therapy if applicable, and consider initiating newer potassium binders to maintain life-saving cardiovascular medications. 1, 2

Classification and Risk Assessment

Your patient has mild hyperkalemia (5.0-5.5 mEq/L) according to the European Society of Cardiology classification. 2 This level rarely causes immediate cardiac arrhythmias, especially in patients with chronic kidney disease, diabetes, or heart failure where potassium levels up to 6.0 mEq/L are often tolerated without ECG changes. 2

First: Rule Out Pseudohyperkalemia

• Repeat the measurement if hemolysis occurred during blood draw, the sample was delayed in processing, or there was traumatic venipuncture 2
• Consider arterial sampling if pseudohyperkalemia is suspected 2

Management Algorithm

Step 1: Identify and Address Reversible Causes

Review all medications that increase potassium: 2

• NSAIDs - discontinue if possible
• Potassium supplements - stop immediately
• Potassium-sparing diuretics (spironolactone, amiloride, triamterene) - assess necessity
• Trimethoprim-sulfamethoxazole - consider alternatives
• Beta-blockers, heparin, calcineurin inhibitors - review dosing

Assess dietary intake: 2

• Eliminate salt substitutes (often contain potassium chloride)
• Reduce high-potassium foods (bananas, melons, orange juice)
• Avoid herbal supplements (noni juice, dandelion, nettle, alfalfa)

Step 2: RAAS Inhibitor Management - Critical Decision Point

The key principle: Do NOT automatically discontinue RAAS inhibitors for mild hyperkalemia, as this increases cardiovascular and renal morbidity and mortality. 1, 2

According to ACC/AHA/HFSA guidelines for mild hyperkalemia (K+ 5.0-5.5 mEq/L): 1

• RAAS inhibitors are NOT usually stopped
• Continue current therapy while addressing other causes
• Only discontinue if concurrent acute conditions are contributing to potassium elevation

European Society of Cardiology recommendations for K+ >5.0 to 6.5 mEq/L: 1

• If patient is on maximum-tolerated guideline-recommended RAAS inhibitor dose: initiate potassium-lowering therapy and continue RAAS inhibitors
• If not on maximum dose: start potassium-lowering therapy when K+ increases above 5.0 mEq/L while maintaining RAAS inhibitors

Step 3: Optimize Diuretic Therapy

• Increase loop or thiazide diuretics to enhance kaliuresis if the patient has adequate kidney function 1
• Caution: Diuretics are less effective with advanced CKD and risk volume depletion, worsening kidney function, and paradoxically reduced potassium excretion 1

Step 4: Correct Metabolic Acidosis

• Treat underlying metabolic acidosis if present, as this contributes to hyperkalemia 1

Step 5: Consider Newer Potassium Binders

Initiate newer potassium-binding agents in patients with chronic hyperkalemia despite optimized diuretic therapy and correction of metabolic acidosis. 1

Two FDA-approved options: 1

• Patiromer (Veltassa) - well-tolerated, documented efficacy in clinical trials
• Sodium zirconium cyclosilicate (SZC/Lokelma) - rapid onset, documented efficacy in clinical trials

These agents are superior to older sodium polystyrene sulfonate (SPS/Kayexalate) due to: 1

• Better palatability leading to improved adherence
• More robust clinical trial evidence
• Fewer adverse effects

National Institute for Health and Care Excellence recommends these agents for use in conjunction with standard care. 1

Monitoring Strategy

• Recheck potassium within 1 week after any intervention 1
• If RAAS inhibitor dose is adjusted, measure potassium and GFR within 1 week per KDIGO guidelines 1
• Establish regular monitoring schedule based on patient's risk factors (CKD stage, diabetes, heart failure, medication regimen) 2, 3

Common Pitfalls to Avoid

1. Prematurely discontinuing RAAS inhibitors: This is the most critical error, as it increases mortality and morbidity in patients with heart failure, CKD, and cardiovascular disease 2, 3

2. Overlooking medication interactions: Many patients are on multiple potassium-raising medications; a systematic review is essential 2

3. Ignoring dietary sources: Patients often underestimate dietary potassium intake and herbal supplements 2, 3

4. Relying solely on diuretics in advanced CKD: Diuretic effectiveness diminishes with declining kidney function 1

5. Not considering newer potassium binders early enough: These agents enable continuation of optimal RAAS inhibitor therapy, which improves long-term outcomes 1, 3, 4